Tübingen registry for autologous stem cell transplantation for severe autoimmune diseases

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00030559

Enrollment

Registered

2023-01-26

Start date

2022-02-20

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M34.0 M32.1 M33.2 M33.1

Interventions

Group 1: Autologous stem cell transplantation - Mobilisation with cyclophosphamide + granulocyte stimulating factor - CD34 + selection - Conditioning with cyclophosphamide + antithymocyte globuline

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Autologous stem cell transplantation for Autoimmune disease Age > 18 years informed consent

Exclusion criteria

Exclusion criteria: Autologous stem cell transplantation for other diseases Age < 18 years

Design outcomes

Primary

Measure	Time frame
Overall survival, percentage of patrients alive after 3 years	—

Secondary

Measure	Time frame
Progression free survival treatment related mortality severe infections secondary autoimmune diseases secondary malignancies	—

Countries

Germany

Contacts

Public ContactJörg Henes

Universitätsklinik Tübingen - Rheumatologie

joerg.henes@med.uni-tuebingen.de07071-2980681

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026